Biotech Hangout

Episode 197 - September 25, 2026

On this week's episode, Sam Fazeli, Yaron Werber, Brian Skorney, and Matt Gline open with the IPO market, noting record average raise sizes even as XBI softens. The group

Episode 196 - September 18, 2026

On this week's episode, Josh Schimmer, Eric Schmidt, Paul Matteis, and guest Adam Feuerstein open with the OpenAI/Hugging Face AI agent controversy, debating whether call

Episode 195 - September 11, 2026

On this week's episode, Tess Cameron, Brian Skorney, Paul Matteis, and Yaron Werber open with a look at markets, noting the XBI slipped just over 3% amid concerns about e

Episode 194 - August 28, 2026

On this week's episode, Daphne Zohar, Eric Schmidt, Sam Fazeli, and Graig Suvannavejh open with a strong week for biotech, partially driven by M&A, noting it's already pa

Episode 193 - August 14, 2026

On this week's episode, Chris Garabedian, Graig Suvannavejh, Paul Matteis, and Tess Cameron open with the biotech market. They describe 2026 as strong but discerning, wit

Episode 192 - August 7, 2026

On this week’s episode, Sam Fazeli, Brian Skorney, Yaron Werber, and Strand Therapeutics CEO Jake Becraft open with the wave of dealmaking and a solid Q2 earnings season,

Episode 191 - July 31, 2026

On this week's episode, Graig Suvannavejh, Tim Opler, Yaron Werber, Paul Matteis, and Brian Skorney kicked off with a review of the market, noting pressure in the XBI des

Episode 190 - July 24, 2026

On this week's episode, Josh Schimmer, Brian Skorney, Eric Schmidt, and Brad Loncar kick off with IPOs and raises, including Scribe's IPO, the first preclinical biotech I

Episode 189 - July 17, 2026

On today’s episode, Yaron Werber, John Maraganore, Sam Fazeli, and Matt Gline open with a discussion of biotech market volatility, with Matt noting that it often seems dr

Episode 188 - July 10, 2026

On this week's episode, Sam Fazeli, Josh Schimmer, Eric Schmidt, Paul Matteis, and special guest STAT's Matt Herper open on the market, noting that despite a wobbly day f

Episode 187 - June 26, 2026

On this week’s episode, Josh Schimmer, Eric Schmidt, Tess Cameron, and Sam Fazeli open by noting the XBI’s continued rise, debating whether biotech is getting ahead of it

Episode 186 - June 12, 2026

On this week’s episode, Graig Suvannavejh, Eric Schmidt, Paul Matteis and Financial Times’ Oliver Barnes kicked off with the biotech market, with the XBI in positive terr

Episode 185 -June 5, 2026

On this week’s episode, Yaron Werber, Tess Cameron, SamFazeli, and Brian Skorney kick off with a look at markets, noting that while AI remains hot, biotech may be cooling

Episode 184 - May 29, 2026

On this week’s episode, Chris Garabedian, Brian Skorney, Graig Suvannavejh, and special guest Ginkgo Bioworks CEO, Jason Kelly, kick off with a market update, highlightin

Episode 183 - May 15, 2026

On this week’s episode, Sam Fazeli, Josh Schimmer, Eric Schmidt, and Tess Cameron kickoff with deals, highlighting the up to $15.2B Hengrui–BMS partnership and the broade

Episode 182 - May 8, 2026

On this week’s episode, Josh Schimmer, Paul Matteis, Eric Schmidt, Yaron Werber, and special guest STAT’s Allison DeAngelis open with what they describe as “a bananas wee

Episode 181 - May 1, 2026

On this week’s episode, Eric Schmidt, Matt Gline, Chris Garabedian, Sam Fazeli, and Graig Suvannavejh open with a discussion on biotech public‑market dynamics, noting sol

Episode 180 - April 17, 2026

On today’s episode, Chris Garabedian, Paul Matteis, Tess Cameron, and special guest Adam Feuerstein kick off with a discussion of the public markets, highlighting the XBI

Episode 179 - April 10, 2026

On this week’s episode, Graig Suvannavejh, Josh Schimmer, Yaron Werber, Sam Fazeli, and special guest Financial Times journalist Oliver Barnes kick off by highlighting th

Episode 178 - April 3, 2026

On this week’s episode, Graig Suvannavejh, Mike Yee, and Eric Schmidt kick off with a look back at biotech deal activity through the first quarter, highlighting a solid,